載入市場數據中...
2026年8月30日星期日
LineVest LogoLineVest

LineVest

企業分析

基於SEC披露的美國上市公司財務分析 — 미국 증시

企業分析
Doosan Robotics (454910.KS) Q1 2026: Revenue Nearly Triples as Consolidated Operating Loss Holds at ₩12.1B付費專屬
企業分析

Doosan Robotics (454910.KS) Q1 2026: Revenue Nearly Triples as Consolidated Operating Loss Holds at ₩12.1B

2026.06.15.0
Amorepacific (090430.KS) Q1 2026: Domestic Profit Surges 65%, COSRX Overseas Down 18%付費專屬
企業分析

Amorepacific (090430.KS) Q1 2026: Domestic Profit Surges 65%, COSRX Overseas Down 18%

2026.06.15.0
Yuhan (000100.KS) Q1 2026: Net Profit +134% on Non-Op Windfall付費專屬
企業分析

Yuhan (000100.KS) Q1 2026: Net Profit +134% on Non-Op Windfall

Yuhan (000100.KS) Q1 2026: Net Profit +134% on Non-Op Windfall *Equity method gains and financial income power the headline profit surge; lazertinib advances to five-market approval while core operati

2026.06.15.3
GS (078930.KS) Q1 2026: Profit Surges 3.5× on Caltex Equity Boom付費專屬
企業分析

GS (078930.KS) Q1 2026: Profit Surges 3.5× on Caltex Equity Boom

GS Holdings (078930.KS) Q1 2026 controlling shareholder net income surged 3.5× YoY to ₩723.2B, driven by one-off inventory gains from a Hormuz-driven crude spike amplifying GS Caltex's equity contribution.

2026.06.14.1
付費專屬
企業分析

Hanwha Solutions (009830.KS) Q1 2026: ₩92.6B Operating Swing as Chemicals Rebound, Qcells Profit Halves

Hanwha Solutions posted consolidated operating profit of ₩92.6 billion in Q1 2026, a 205.5% year-on-year surge from ₩30.3 billion, ending a two-year operating loss streak that had consumed ₩1.37 trill

2026.06.14.1
Daeduck (008060.KS) Q1 2026: AI Substrates Flip Profit to ₩51.3B付費專屬
企業分析

Daeduck (008060.KS) Q1 2026: AI Substrates Flip Profit to ₩51.3B

2026.06.14.0
LG Display (034220.KS) Q1 2026: Operating Profit Surges 4.4x as ₩13.7T Debt Swells Net Loss to ₩575.7B付費專屬
企業分析

LG Display (034220.KS) Q1 2026: Operating Profit Surges 4.4x as ₩13.7T Debt Swells Net Loss to ₩575.7B

2026.06.13.1
LG Display (034220.KS) Q1 2026: Profit 4× but ₩576B Net Loss Bites付費專屬
企業分析

LG Display (034220.KS) Q1 2026: Profit 4× but ₩576B Net Loss Bites

2026.06.13.0
SK Biopharma (326030.KS) Q1 2026: Cenobamate Lifts Operating Profit 250%, Margin Hits 39%付費專屬
企業分析

SK Biopharma (326030.KS) Q1 2026: Cenobamate Lifts Operating Profit 250%, Margin Hits 39%

Single-drug operating leverage transforms SK Biopharmaceuticals from loss-making drug launcher to high-margin cash generator — operating margin more than doubles year-over-year.

2026.06.13.6
Hankook Tire (161390.KS) Q1 2026: Margin Hits 9.5%, Operating Profit Surges 43%付費專屬
企業分析

Hankook Tire (161390.KS) Q1 2026: Margin Hits 9.5%, Operating Profit Surges 43%

2026.06.13.0
Hanjin KAL (180640.KS) Q1 2026: +17% Profit Hides 69% Equity Income Drop付費專屬
企業分析

Hanjin KAL (180640.KS) Q1 2026: +17% Profit Hides 69% Equity Income Drop

2026.06.12.0
DB HiTek (000990.KS) FY2025: 45% Profit Surge, 8-Inch Fab at 92%付費專屬
企業分析

DB HiTek (000990.KS) FY2025: 45% Profit Surge, 8-Inch Fab at 92%

2026.06.12.0